Middle East & Africa Biosimilars Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2028 - COVID-19 Impact and Regional Analysis by Disease Indication (Cancer, Diabetes, Autoimmune Diseases, and Other Diseases), Drug Class (Granulocyte Colony-Stimulating Factors, Human Growth Hormone, Insulin, TNF Blockers & Monoclonal Antibodies, Erythropoietin-Stimulating Agents, and Others), Route of Administration (Intravenous, Subcutaneous, and Others), and End User (Hospitals, Speciality Clinics, Homecare, and Others)

No. of Pages: 158    |    Report Code: BMIRE00028364    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
Middle East & Africa Biosimilars Market

1.           Introduction

1.1         Scope of the Study

1.2         The Insight Partners Research Report Guidance

1.3         Market Segmentation

1.3.1        Middle East & Africa Biosimilars Market – by Disease Indication

1.3.2        Middle East & Africa Biosimilars Market – by Drug class

1.3.3        Middle East & Africa Biosimilars Market – by Route of Administration

1.3.4        Middle East & Africa Biosimilars Market – by End User

1.3.5        Middle East & Africa Biosimilars Market – by Country

2.           Middle East & Africa Biosimilars Market – Key Takeaways

3.        Research Methodology

3.1         Coverage

3.2         Secondary Research

3.3         Primary Research

4.           Middle East & Africa Biosimilars Market – Market Landscape

4.1         Overview

4.2         Middle East & Africa PEST Analysis

4.3         Expert’s Opinion

5.           Middle East & Africa Biosimilars Market – Key Market Dynamics

5.1         Market Drivers

5.1.1        Increasing Prevalence of Chronic Diseases

5.1.2        Cost Effectiveness of Biosimilar Drugs

5.1.3        Rising Approvals of Biosimilars

5.2         Market Restraints

5.2.1        High-Cost Involvement and Complexities in Biosimilar Product Manufacturing

5.3         Market Opportunities

5.3.1        Patent Expiry of Blockbuster Biologics

5.4         Future Trend

5.4.1        Collaborations for Biosimilars and Clinical Trials

5.5         Impact analysis

6.           Biosimilars Market – Middle East & Africa Analysis

6.1         Middle East & Africa Biosimilars Market Revenue Forecast and Analysis

7.           Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 – by Disease Indication

7.1         Overview

7.2         Middle East & Africa Biosimilars Market Revenue Share, by disease indication 2021 & 2028 (%)

7.3         Cancer

7.3.1        Overview

7.3.2        Cancer: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

7.4         Diabetes

7.4.1        Overview

7.4.2        Diabetes: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

7.5         Autoimmune Diseases

7.5.1        Overview

7.5.2        Autoimmune Diseases: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

7.5.3        Psoriasis:

7.5.3.1          Overview

7.5.3.2          Psoriasis: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

7.5.4        Arthritis:

7.5.4.1          Overview

7.5.4.2          Arthritis: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

7.5.5        Others:

7.5.5.1          Overview

7.5.5.2          Others: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

7.6         Others Disease Indications

7.6.1        Overview

7.6.2        Others Disease Indications: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

8.           Middle East & Africa Biosimilars Market Analysis and Forecast to 2028 – by Drug Class

8.1         Overview

8.2         Middle East & Africa Biosimilars Market, by Drug class 2021 & 2028 (%)

8.3         Granulocyte colony-stimulating factors

8.3.1        Overview

8.3.2        Granulocyte colony-stimulating factors Drug class: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028  (US$ Million)

8.4         Insulin

8.4.1        Overview

8.4.2        Insulin Drug class: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

8.5         TNF Blockers and Monoclonal Antibodies

8.5.1        Overview

8.5.2        TNF Blockers and Monoclonal Antibodies Drug class: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028  (US$ Million)

8.6         Others

8.6.1        Overview

8.6.2        Others Drug class: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

9.           Middle East & Africa Biosimilars Market Analysis and Forecasts to 2028 – by Route of Administration

9.1         Overview

9.2         Middle East & Africa Biosimilars Market, by Application 2021 & 2028 (%)

9.3         Intravenous

9.3.1        Overview

9.3.2        Intravenous: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

9.4         Subcutaneous

9.4.1        Overview

9.4.2        Subcutaneous: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

9.5         Others

9.5.1        Overview

9.5.2        Others: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

10.        Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 – by End User

10.1      Overview

10.2      Middle East & Africa Biosimilars Market Revenue Share, by End User 2021 & 2028 (%)

10.3      Hospitals

10.3.1     Overview

10.3.2     Hospitals: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

10.4      Specialty Clinics

10.4.1     Overview

10.4.2     Specialty Clinics: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

10.5      Homecare

10.5.1     Overview

10.5.2     Homecare: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

10.6      Other

10.6.1     Overview

10.6.2     Other: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

11.        Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 – Country Analysis

11.1      Overview

11.1.1.1       Saudi Arabia: Biosimilar Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.1.1       Overview

11.1.1.1.2       Saudi Arabia: Biosimilar Market - Revenue and Forecast to 2028 (US$ Million)

11.1.1.1.3       Saudi Arabia: Biosimilar Market, by Disease Indication, 2019–2028 (US$ Million)

11.1.1.1.3.1     Saudi Arabia: Biosimilar Market, by Autoimmune Diseases, 2019–2028 (US$ Million)

11.1.1.1.4       Saudi Arabia: Biosimilar Market, by Drug Class, 2019–2028 (US$ Million)

11.1.1.1.5       Saudi Arabia: Biosimilar Market, by Route of Administration, 2019–2028 (US$ Million)

11.1.1.1.6       Saudi Arabia: Biosimilar Market, by End User, 2019–2028 (US$ Million)

11.1.1.2       South Africa: Biosimilar Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.2.1       South Africa: Biosimilar Market - Revenue and Forecast to 2028 (US$ Million)

11.1.1.2.2       South Africa: Biosimilar Market, by Disease Indication, 2019–2028 (US$ Million)

11.1.1.2.2.1     South Africa: Biosimilar Market, by Autoimmune Diseases, 2019–2028 (US$ Million)

11.1.1.2.3       South Africa: Biosimilar Market, by Drug Class, 2019–2028 (US$ Million)

11.1.1.2.4       South Africa: Biosimilar Market, by Route of Administration, 2019–2028 (US$ Million)

11.1.1.2.5       South Africa: Biosimilar Market, by End User, 2019–2028 (US$ Million)

11.1.1.3       UAE: Biosimilar Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.3.1       UAE: Biosimilar Market - Revenue and Forecast to 2028 (US$ Million)

11.1.1.3.2       UAE: Biosimilar Market, by Disease Indication, 2019–2028 (US$ Million)

11.1.1.3.2.1     UAE: Biosimilar Market, by Autoimmune Diseases, 2019–2028 (US$ Million)

11.1.1.3.3       UAE: Biosimilar Market, by Drug Class, 2019–2028 (US$ Million)

11.1.1.3.4       UAE: Biosimilar Market, by Route of Administration, 2019–2028 (US$ Million)

11.1.1.3.5       UAE: Biosimilar Market, by End User, 2019–2028 (US$ Million)

11.1.1.4       Rest of Middle East and Africa: Biosimilar Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.4.1       Rest of Middle East and Africa: Biosimilar Market - Revenue and Forecast to 2028 (US$ Million)

11.1.1.4.2       Rest of Middle East and Africa: Biosimilar Market, by Disease Indication, 2019–2028 (US$ Million)

11.1.1.4.2.1     Rest of Middle East and Africa: Biosimilar Market, by Autoimmune Diseases, 2019–2028 (US$ Million)

11.1.1.4.3       Rest of Middle East and Africa: Biosimilar Market, by Drug Class, 2019–2028 (US$ Million)

11.1.1.4.4       Rest of Middle East and Africa: Biosimilar Market, by Route of Administration, 2019–2028 (US$ Million)

11.1.1.4.5       Rest of Middle East and Africa: Biosimilar Market, by End User, 2019–2028 (US$ Million)

12.        Biosimilars Market – Industry Landscape

12.1      Overview

12.2      Growth Strategies in the Biosimilars Market

12.3      Inorganic Growth Strategies

12.3.1     Overview

12.4      Organic Growth Strategies

12.4.1     Overview

13.        Company Profiles

13.1      Amgen Inc

13.1.1     Key Facts

13.1.2     Business Description

13.1.3     Products and Services

13.1.4     Financial Overview

13.1.5     SWOT Analysis

13.1.6     Key Developments

13.2      Sanofi SA

13.2.1     Key Facts

13.2.2     Business Description

13.2.3     Products and Services

13.2.4     Financial Overview

13.2.5     SWOT Analysis

13.2.6     Key Developments

13.3      Biocon Ltd

13.3.1     Key Facts

13.3.2     Business Description

13.3.3     Products and Services

13.3.4     Financial Overview

13.3.5     SWOT Analysis

13.3.6     Key Developments

13.4      Eli Lilly and Co

13.4.1     Key Facts

13.4.2     Business Description

13.4.3     Products and Services

13.4.4     Financial Overview

13.4.5     SWOT Analysis

13.4.6     Key Developments

13.5      Sandoz AG

13.5.1     Key Facts

13.5.2     Business Description

13.5.3     Products and Services

13.5.4     Financial Overview

13.5.5     SWOT Analysis

13.5.6     Key Developments

13.6      Teva Pharmaceutical Industries Ltd

13.6.1     Key Facts

13.6.2     Business Description

13.6.3     Products and Services

13.6.4     Financial Overview

13.6.5     SWOT Analysis

13.6.6     Key Developments

13.7      Pfizer Inc

13.7.1     Key Facts

13.7.2     Business Description

13.7.3     Products and Services

13.7.4     Financial Overview

13.7.5     SWOT Analysis

13.7.6     Key Developments

13.8      Dr. Reddy's Laboratories Ltd

13.8.1     Key Facts

13.8.2     Business Description

13.8.3     Products and Services

13.8.4     Financial Overview

13.8.5     SWOT Analysis

13.8.6     Key Developments

14.        Appendix

14.1      About The Insight Partners

14.2      Glossary of Terms

 

 

LIST OF TABLES

Table 1.             Comparison Between Different Drug Developments

Table 2.             Saudi Arabia Biosimilar Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)

Table 3.             Saudi Arabia Biosimilar Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)

Table 4.             Saudi Arabia Biosimilar Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 5.             Saudi Arabia Biosimilar Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 6.             Saudi Arabia Biosimilar Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 7.             South Africa Biosimilar Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)

Table 8.             South Africa Biosimilar Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)

Table 9.             South Africa Biosimilar Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 10.          South Africa Biosimilar Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 11.          South Africa Biosimilar Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 12.          UAE Biosimilar Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)

Table 13.          UAE Biosimilar Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)

Table 14.          UAE Biosimilar Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 15.          UAE Biosimilar Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 16.          UAE Biosimilar Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 17.          Rest of Middle East and Africa Biosimilar Market, by Disease Indication – Revenue and Forecast to 2028 (US$ Million)

Table 18.          Rest of Middle East and Africa Biosimilar Market, by Autoimmune Diseases – Revenue and Forecast to 2028 (US$ Million)

Table 19.          Rest of Middle East and Africa Biosimilar Market, by Drug Class – Revenue and Forecast to 2028 (US$ Million)

Table 20.          Rest of Middle East and Africa Biosimilar Market, by Route of Administration – Revenue and Forecast to 2028 (US$ Million)

Table 21.          Rest of Middle East and Africa Biosimilar Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 22.          Recent Inorganic Growth Strategies in the Biosimilars Market

Table 23.          Recent Organic Growth Strategies in the Biosimilars Market

Table 24.          Glossary of Terms

 

 

LIST OF FIGURES

Figure 1.           Middle East & Africa Biosimilars Market Segmentation

Figure 2.           Middle East & Africa Biosimilars Market, by Country

Figure 3.           Middle East & Africa Biosimilars Market Overview

Figure 4.           Cancer Segment Held Largest Share of Type Segment in Middle East & Africa Biosimilars Market

Figure 5.           UAE Expected to Show Remarkable Growth During Forecast Period

Figure 6.           Middle East & Africa: PEST Analysis

Figure 7.           Experts’ Opinion

Figure 8.           Middle East & Africa Biosimilars Market Impact Analysis of Drivers and Restraints

Figure 9.           Middle East & Africa Biosimilars Market – Revenue Forecast and Analysis – 2020–2028

Figure 10.        Middle East & Africa Biosimilars Market Revenue Share, by disease indication 2021 & 2028 (%)

Figure 11.        Cancer: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 12.        Diabetes: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 13.        Autoimmune Diseases: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 14.        Psoriasis: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 15.        Arthritis: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 16.        Others: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 17.        Others Disease Indications: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 18.        Middle East & Africa Biosimilars Market, by Drug class 2021 & 2028 (%)

Figure 19.        Granulocyte colony-stimulating factors Drug class: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028  (US$ Million)

Figure 20.        Insulin Drug class: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 21.        TNF Blockers and Monoclonal Antibodies Drug class: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028  (US$ Million)

Figure 22.        Others Drug class: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 23.        Middle East & Africa Biosimilars Market, by Application 2021 & 2028 (%)

Figure 24.        Intravenous: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 25.        Subcutaneous: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 26.        Others: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 27.        Middle East & Africa Biosimilars Market Revenue Share, by End User 2021 & 2028 (%)

Figure 28.        Hospitals: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 29.        Specialty Clinics: Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 30.        Homecare: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 31.        Other: Middle East & Africa Biosimilars Market – Revenue and Forecast to 2028 (US$ Million)

Figure 32.        Middle East and Africa: Biosimilar Market, by Key Country – Revenue (2022) (US$ Million)

Figure 33.        Middle East and Africa: Biosimilar Market, by Country, 2021 & 2028 (%)

Figure 34.        Saudi Arabia Biosimilar Market Revenue and Forecast to 2028 (USD Million)

Figure 35.        South Africa Biosimilar Market Revenue and Forecast to 2028 (USD Million)

Figure 36.        UAE Biosimilar Market Revenue and Forecast to 2028 (USD Million)

Figure 37.        Rest of Middle East and Africa Biosimilar Market Revenue and Forecast to 2028 (USD Million)

Figure 38.        Growth Strategies in the Biosimilars Market

 

The List of Companies - Middle East & Africa Biosimilars Market

  1. Amgen Inc
  2. Sanofi SA  
  3. Biocon Ltd
  4. Eli Lilly and Co
  5. Sandoz AG
  6. Teva Pharmaceutical Industries Ltd
  7. Pfizer Inc
  8. Dr. Reddy's Laboratories Ltd